health | mecfa

MECFA Blog

Claire’s Place Foundation Launches COVID-19 Emergency Fund for People with Cystic Fibrosis

Claire’s Place Foundation medical expert recommends all with cystic fibrosis self-quarantine immediately Claire’s Place Foundation, a...

How cystic fibrosis can manifest in the gastrointestinal system

In the February 2020 issue of Contemporary Pediatrics, Drs. Anna Reed and Darla Shores provide a briefing on the care of cystic fibrosis...

‘Rare Barometer’ Program Helps Eurordis Shape EU Rare Disease Policy

People with rare diseases know that the right government policies can make a big difference in the quality of their own lives, and those...

Lovelace Biomedical Talks About Developing Novel Therapies for Cystic Fibrosis Month

May is Cystic Fibrosis (CF) month. Lovelace has been working in respiratory research for over 70 years, and has been using gene therapy...

Incidence of Non-CF Bronchiectasis is Rising in Germany, Study Reports

The incidence of non-cystic fibrosis bronchiectasis is rising in Germany, which necessitates a better understanding of the economic...

Decreasing Acidity of Airway Liquid in Newborn CF Patients May Reduce Infection Risk, Study Suggests

Normalizing the acidity in the thin layer of liquid covering the airways of newborns with cystic fibrosis might make them more resistant...

Breathing space: Inhalable biologics interest prompts Intertek expansion

Interest in inhaled biologics is increasing says Intertek, which has announced plans to expand its testing facility in Melbourn, near...

Choline Supplementation Improves Lung Function, Liver Health in CF Patients, Study Shows

Choline supplementation improves lung function and liver health in people with cystic fibrosis (CF), and should be considered as a...

Mucus and Inflammation, Rather Than Infections, are Early Drivers of Lung Disease in CF, Study Says

Early accumulation of abnormally thick mucus and inflammation in the lungs, rather than bacterial infections, may be the initial trigger...

Virus that Infects Bacteria Turns Immune Response Away from P. aeruginosa, Study Shows

Pseudomonas aeruginosa, the most common bacteria found in cystic fibrosis (CF) patients, uses a virus to go unnoticed by the host immune...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p